Global /United States /Healthcare /Biotechnology /LRMR

Larimar Therapeutics, Inc.

LRMR

• NASDAQ: LRMR • Delayed

4.35USD -1.3%

As of 14 June 2026, Larimar Therapeutics, Inc. has a market cap of $449.81M USD, ranking #15864 globally and #2713 in the United States. It ranks #1418 in the Healthcare sector, and #276 in the Biotechnology industry.

Global Rank

15864

Country Rank

2713

Sector Rank

1418

Industry Rank

276

Key Stats

Market Cap

$449.81MUSD

Enterprise Value

$317.03MUSD

EBITDA (TTM)

-$172.15MUSD

Net Income (TTM)

-$165.67MUSD

PB Ratio

4.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Carole Ben-Maimon open_in_new

Employees

Website

larimartx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.3%	-4.7%	-6%	18%	-0.1%	14%	85%	-8.1%	-70%

News

LRMR Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	LRMR Larimar Therapeutics Inc ISIN: US5171251003 Shares Out.: Shares Outstanding: 103.883M¹ Shares Float: 50.606M² TV: TradingView: NASDAQ: LRMR SA: Stock Analysis: NASDAQ: LRMR YF: Yahoo Finance: LRMR GF: Google Finance: NASDAQ: LRMR NQ: NASDAQ: LRMR BA: Barron's: LRMR MS: Morningstar: XNAS: LRMR	4.35 USD	TV: TradingView: NASDAQ: LRMR SA: Stock Analysis: NASDAQ: LRMR YF: Yahoo Finance: LRMR GF: Google Finance: NASDAQ: LRMR NQ: NASDAQ: LRMR BA: Barron's: LRMR MS: Morningstar: XNAS: LRMR

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 40K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 35K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 6K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 6K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 5K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 4K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 11K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 10K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 9K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 9K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 6K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 6K%	-	Germany

chevron_leftBack